Harvard Bioscience, Inc. Stock price

Equities

HBIO

US4169061052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.2 USD +4.48% Intraday chart for Harvard Bioscience, Inc. -4.55% -21.50%
Sales 2024 * 114M Sales 2025 * 126M Capitalization 182M
Net income 2024 * - Net income 2025 * 3M EV / Sales 2024 * 1.6 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.45 x
P/E ratio 2024 *
-840 x
P/E ratio 2025 *
56 x
Employees 404
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.48%
1 week-4.55%
Current month-3.00%
1 month-4.98%
3 months-23.50%
6 months-0.24%
Current year-21.50%
More quotes
1 week
3.92
Extreme 3.92
4.37
1 month
3.84
Extreme 3.84
4.61
Current year
3.84
Extreme 3.84
5.44
1 year
3.45
Extreme 3.4502
6.29
3 years
1.98
Extreme 1.98
8.75
5 years
1.39
Extreme 1.39
8.75
10 years
1.39
Extreme 1.39
8.75
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 15-04-27
Director of Finance/CFO 52 22-04-30
Chief Operating Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 65 15-04-27
Director/Board Member 56 19-09-02
Director/Board Member 58 14-11-05
More insiders
Date Price Change Volume
24-03-27 4.2 +4.48% 81,812
24-03-26 4.02 -2.66% 87,104
24-03-25 4.13 -0.96% 38,562
24-03-22 4.17 -4.36% 93,246
24-03-21 4.36 -0.91% 53,829

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. It has organized its product line activities into two product families, cellular and molecular technology (CMT) and Preclinical. Its CMT product family is composed of products supporting research related to molecular, cellular organ and organoid technologies, with additional application in the field of bio-production of pharmaceuticals and therapeutics. Its preclinical product family includes four business lines that support the preclinical research and testing phase for drug development, and in particular testing related to data collection and analysis for safety and regulatory compliance. Its brands include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs and others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.2 USD
Average target price
7 USD
Spread / Average Target
+66.67%
Consensus
  1. Stock
  2. Equities
  3. Stock Harvard Bioscience, Inc. - Nasdaq